The future of cancer immunotherapy: microenvironment-targeting combinations
YR Murciano-Goroff, AB Warner, JD Wolchok - Cell research, 2020 - nature.com
Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …
patients currently respond. The etiologies of primary and secondary resistance to …
Metabolism of amino acids in cancer
Metabolic reprogramming has been widely recognized as a hallmark of malignancy. The
uptake and metabolism of amino acids are aberrantly upregulated in many cancers that …
uptake and metabolism of amino acids are aberrantly upregulated in many cancers that …
mRECIST for HCC: performance and novel refinements
JM Llovet, R Lencioni - Journal of hepatology, 2020 - Elsevier
Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020)
PK Haber, M Puigvehí, F Castet, V Lourdusamy… - Gastroenterology, 2021 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment
R Missiaen, NM Anderson, LC Kim, B Nance… - Cell metabolism, 2022 - cell.com
Hepatocellular carcinoma (HCC) is a typically fatal malignancy exhibiting genetic
heterogeneity and limited therapy responses. We demonstrate here that HCCs consistently …
heterogeneity and limited therapy responses. We demonstrate here that HCCs consistently …
Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
Arginine signaling and cancer metabolism
Simple Summary In this review, we describe arginine's role as a signaling metabolite,
epigenetic regulator and mitochondrial modulator in cancer cells, and summarize recent …
epigenetic regulator and mitochondrial modulator in cancer cells, and summarize recent …
Amino acids and their transporters in T cell immunity and cancer therapy
W Wang, W Zou - Molecular cell, 2020 - cell.com
Metabolism reprogramming is critical for both cancer progression and effective immune
responses in the tumor microenvironment. Amino acid metabolism in different cells and their …
responses in the tumor microenvironment. Amino acid metabolism in different cells and their …
Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy
Metabolic programming in the tumor microenvironment (TME) alters tumor immunity and
immunotherapeutic response in tumor-bearing mice and patients with cancer. Here, we …
immunotherapeutic response in tumor-bearing mice and patients with cancer. Here, we …
Rewiring urea cycle metabolism in cancer to support anabolism
Cancer cells reprogramme metabolism to maximize the use of nitrogen and carbon for the
anabolic synthesis of macromolecules that are required during tumour proliferation and …
anabolic synthesis of macromolecules that are required during tumour proliferation and …